New test could help enhance decision-making in treatment of chronic kidney disease in type 2 diabetics

Proteomics International Laboratories Ltd (ASX: PIQ) has announced the publication of a peer-reviewed Australian clinical utility study demonstrating that the PromarkerD blood test provides actionable information that significantly changes how…

Continue Reading

News Source: medicalxpress.com